MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

MGI and HKBU Partner to Enhance Anti-Doping Efforts with Advanced Sequencing Technology

NextEdge Admin

26 Jul 2024

2 min 58 sec

MGI Tech Co., Ltd. ("MGI"), a leader in life science innovation, has announced a collaboration with renowned geneticist Professor Yannis Pitsiladis of Hong Kong Baptist University to advance sports and anti-doping research. Utilizing MGI's cutting-edge DNBSEQ sequencers and automation platforms, the partnership aims to enhance the detection of blood doping through the power of omics technologies.

Professor Pitsiladis, a pioneer in anti-doping research and a member of the International Olympic Committee Medical and Scientific Commission, highlighted the critical need for sophisticated detection methods, given that an estimated 6% of top athletes engage in doping. He emphasized that high-throughput sequencing could identify blood doping practices, the methods used, and the timing of these actions. MGI's advanced sequencing tools are set to optimize what was previously a labor-intensive, costly, and time-consuming process.

During the Paris 2024 Summer Olympics, Professor Pitsiladis will be part of a panel discussion hosted by the World Olympians Association (WOA) at OLY House Paris 2024 @ Caisse d'Epargne. The event, taking place on July 29, is part of Hong Kong Baptist University's two-day program. MGI will also exhibit its innovative portable DNBSEQ-E25 sequencer, ultra-high speed DNBSEQ-G99 platform, and AlphaTool automated pipetting robot, showcasing their technologies to Olympians worldwide.

On July 22, Professor Pitsiladis, in collaboration with MGI and other international researchers, published an article titled “Practical steps to develop a transcriptomic test for blood doping” in Translational Exercise Biomedicine. The article outlines key considerations for developing a transcriptomic test for blood doping and aims to guide international research and anti-doping centers in aligning with World Anti-Doping Agency standards.

“We are proud to support valuable research in sports performance and anti-doping through omics,” said Duncan Yu, President of MGI. “MGI is committed to driving significant advancements and groundbreaking applications in this field through intelligent innovation.”